Tista' taqra bil- Malti.
The European Commission has approved a 5th contract with CureVac for up to 405 million doses of the Covid-19 vaccine.
The contract provides for the initial purchase of 225 million doses on behalf of all EU Member States, plus an option to request up to a further 180 million doses, to be supplied once a vaccine has proven to be safe and effective against COVID-19.
The other contracts are signed with AstraZeneca, Sanofi-GSK, Janssen Pharmaceutica NV. The final contract is signed with BioNtech-Pfizer, which plan to apply for emergency approval to use the vaccine by the end of November. This vaccine can prevent more than 90% of people from getting the virus. It has been tested on 43,500 people in six countries and no safety concerns have been raised.
There have also been successful exploratory talks with Moderna.
CureVac is pioneering the development of a completely new class of vaccines based on messenger RNA (mRNA), transported into cells by lipid nanoparticles. The vaccine platform has been developed over the last decade. The basic principle is the use of this molecule as a data carrier for information, with the help of which the body itself can produce its own active substances to combat various diseases.